Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Market Definitions
1.1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Segment Snapshot
2.5 Competitive Landscape Snapshot
Chapter 3 Sepsis Diagnostics Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Impact Analysis
3.2.1.1 Increase In Prevalence Of Sepsis
3.2.1.2 Rise In Incidence Of Hospital-Acquired Infections
3.2.1.3 Increase In The Number Of Pneumonia Cases
3.2.1.4 Approval And Launch Of Advanced Sepsis Diagnostic System
3.2.2 Market Restraint Analysis
3.2.2.1 High Cost Of Automated Diagnostic Instruments
3.2.2.2 Lack Of Awareness About Sepsis
3.2.3 Industry Challenges
3.2.3.1 Scientific And Clinical Challenges Associated With Sepsis
3.3 Sepsis Diagnostics: Market Analysis Tools
3.3.1 Porter’s Analysis
3.3.2 Sepsis Diagnostics – Macroeconomic Analysis
Chapter 4 Sepsis Diagnostics Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)
4.1 Sepsis Diagnostics Market: Product Movement Analysis
4.2 Sepsis Diagnostics Market Estimates & Forecast, By Product (USD Million)
4.2.1 Instrument
4.2.2 Blood Culture Media
4.2.3 Assay Kits And Reagents
4.2.4 Software
Chapter 5 Sepsis Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)
5.1 Sepsis Diagnostics Market: Technology Movement Analysis
5.2 Sepsis Diagnostics Market Estimates & Forecast, By Technology (USD Million)
5.2.1 Microbiology
5.2.2 Molecular Diagnostics
5.2.2.1 Polymerase Chain Reaction (Pcr)
5.2.2.2 Dna Microarrays
5.2.2.3 Syndromic Panel Testing
5.2.2.4 Others
5.2.3 Immunoassays
5.2.4 Flow Cytometry
5.2.5 Others
Chapter 6 Sepsis Diagnostics Market: Segment Analysis, By Pathogen, 2018 - 2030 (USD Million)
6.1 Sepsis Diagnostics Market: Pathogen Movement Analysis
6.2 Sepsis Diagnostics Market Estimates & Forecast, By Pathogen (USD Million)
6.2.1 Bacterial Sepsis
6.2.1.1 Gram-Positive Bacteria
6.2.1.2 Gram-Negative Bacteria
6.2.2 Fungal Sepsis
6.2.3 Viral Sepsis And Others
Chapter 7 Sepsis Diagnostics Market: Segment Analysis, By Testing Type, 2018 - 2030 (USD Million)
7.1 Sepsis Diagnostics Market: Testing Type Movement Analysis
7.2 Sepsis Diagnostics Market Estimates & Forecast, By Testing Type (USD Million)
7.2.1 Laboratory Testing
7.2.2 Point-Of-Care Testing
Chapter 8 Sepsis Diagnostics Market: Segment Analysis, By Method, 2018 - 2030 (USD Million)
8.1 Sepsis Diagnostics Market: Method Movement Analysis
8.2 Sepsis Diagnostics Market Estimates & Forecast, By Method (USD Million)
8.2.1 Automated Diagnostics
8.2.2 Conventional Diagnostics
Chapter 9 Sepsis Diagnostics Market: Segment Analysis, By End-User, 2018 - 2030 (USD Million)
9.1 Sepsis Diagnostics Market: End-User Movement Analysis
9.2 Sepsis Diagnostics Market Estimates & Forecast, By End-User (USD Million)
9.2.1 Hospitals & Clinics
9.2.2 Pathology & Reference Laboratories
9.2.3 Research Institutes And Others
Chapter 10 Sepsis Diagnostic Market: Regional Estimates And Trend Analysis, By Product, By Technology, By Pathogen, By Testing Type, By Method, & By End-User
10.1 Sepsis Diagnostic Market: Regional Outlook
Chapter 11 Competitive Landscape
11.1 Company Categorization
11.2 Company Market Positioning
11.2.1 Market Leaders
11.2.1.1 Sepsis Diagnostics Market Share Analysis, 2022
11.3 Company Profiles
11.3.1 Biomérieux Sa
11.3.1.1 Company Overview
11.3.1.2 Financial Performance
11.3.1.3 Product Benchmarking
11.3.1.4 Strategic Initiatives
11.3.2 Becton, Dickinson And Company (Bd)
11.3.2.1 Company Overview
11.3.2.2 Financial Performance
11.3.2.3 Product Benchmarking
11.3.2.4 Strategic Initiatives
11.3.3 Thermo Fisher Scientific, Inc.
11.3.3.1 Company Overview
11.3.3.2 Financial Performance
11.3.3.3 Product Benchmarking
11.3.3.4 Strategic Initiatives
11.3.4 F. Hoffmann-La Roche
11.3.4.1 Company Overview
11.3.4.2 Financial Performance
11.3.4.3 Product Benchmarking
11.3.4.4 Strategic Initiatives
11.3.5 Luminex Corporation
11.3.5.1 Company Overview
11.3.5.2 Financial Performance
11.3.5.3 Product Benchmarking
11.3.5.4 Strategic Initiatives
11.3.6 Danaher
11.3.6.1 Cepheid
11.3.6.1.1 Company Overview
11.3.6.1.2 Financial Performance
11.3.6.1.3 Product Benchmarking
11.3.6.1.4 Strategic Initiatives
11.3.6.2 Beckman Coulter, Inc.
11.3.6.2.1 Company Overview
11.3.6.2.2 Financial Performance
11.3.6.2.3 Product Benchmarking
11.3.6.2.4 Strategic Initiatives
11.3.7 Luminex Corporation
11.3.7.1 Company Overview
11.3.7.2 Financial Performance
11.3.7.3 Product Benchmarking
11.3.7.4 Strategic Initiatives
11.3.8 Bruker Corporation
11.3.8.1 Company Overview
11.3.8.2 Financial Performance
11.3.8.3 Product Benchmarking
11.3.8.4 Strategic Initiatives
11.3.9 Amara Health Analytics
11.3.9.1 Company Overview
11.3.9.2 Financial Performance
11.3.9.3 Product Benchmarking
11.3.9.4 Strategic Initiatives
11.3.10 Cepheid
11.3.10.1 Company Overview
11.3.10.2 Financial Performance
11.3.10.3 Product Benchmarking
11.3.10.4 Strategic Initiatives
11.3.11 Beckman Coulter, Inc.
11.3.11.1 Company Overview
11.3.11.2 Financial Performance
11.3.11.3 Product Benchmarking
11.3.11.4 Strategic Initiatives
11.3.12 Bruker Corporation
11.3.12.1 Company Overview
11.3.12.2 Financial Performance
11.3.12.3 Product Benchmarking
11.3.12.4 Strategic Initiatives
11.3.13 Immunexpress, Inc.
11.3.13.1 Company Overview
11.3.13.2 Financial Performance
11.3.13.3 Product Benchmarking
11.3.13.4 Strategic Initiatives
11.3.14 Koninklijke Philips N.V.
11.3.14.1 Company Overview
11.3.14.2 Financial Performance
11.3.14.3 Product Benchmarking
11.3.14.4 Strategic Initiatives
